Crescita Stock Based Compensation from 2010 to 2026
| CTX Stock | CAD 0.49 0.02 4.26% |
Stock Based Compensation | First Reported 2015-03-31 | Previous Quarter 28 K | Current Value 7 K | Quarterly Volatility 32.5 K |
Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 55.6 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.67. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
Crescita | Stock Based Compensation |
Evaluating Crescita Therapeutics's Stock Based Compensation across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Crescita Therapeutics's fundamental strength.
Latest Crescita Therapeutics' Stock Based Compensation Growth Pattern
Below is the plot of the Stock Based Compensation of Crescita Therapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Crescita Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crescita Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation | 10 Years Trend |
|
Stock Based Compensation |
| Timeline |
Crescita Stock Based Compensation Regression Statistics
| Arithmetic Mean | 214,509 | |
| Geometric Mean | 203,640 | |
| Coefficient Of Variation | 30.36 | |
| Mean Deviation | 53,284 | |
| Median | 245,000 | |
| Standard Deviation | 65,133 | |
| Sample Variance | 4.2B | |
| Range | 260K | |
| R-Value | (0.39) | |
| Mean Square Error | 3.9B | |
| R-Squared | 0.15 | |
| Significance | 0.13 | |
| Slope | (4,967) | |
| Total Sum of Squares | 67.9B |
Crescita Stock Based Compensation History
About Crescita Therapeutics Financial Statements
Crescita Therapeutics investors utilize fundamental indicators, such as Stock Based Compensation, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation | 162.9 K | 169.7 K | |
| Stock Based Compensation To Revenue | 0.01 | 0.01 |
Pair Trading with Crescita Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crescita Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crescita Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Crescita Stock
The ability to find closely correlated positions to Crescita Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crescita Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crescita Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crescita Therapeutics to buy it.
The correlation of Crescita Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crescita Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crescita Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crescita Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Crescita Stock
Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.